Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations

被引：0
|
作者：
Tsurumi, K. [1 ]
Suzuki, A. [1 ]
Watanabe, K. [1 ]
Fukuhara, T. [1 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.415
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P39-7
引用
收藏
页码：S1378 / S1378
页数：1
相关论文
共 50 条
  • [21] Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
    Goto, Y.
    Takahashi, K.
    Saito, H.
    Ogasawara, T.
    Shindoh, J.
    Kimura, T.
    Sugino, Y.
    Kojima, E.
    Nomura, F.
    Nakanishi, T.
    Nozaki, Y.
    Takeyama, Y.
    Imaizumi, K.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S469 - S470
  • [22] A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, M.
    Hua, Y.
    Su, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1735 - S1735
  • [23] Pemetrexed (Pem), carboplatin (Cb), and bevacizumab (Bev) in patients with nonsquamous NSCLC without or with activating EGFR mutation (CJLSG0909/0910).
    Kimura, Tomoki
    Taniguchi, Hiroyuki
    Ogasawara, Tomohiko
    Kondo, Masashi
    Suzuki, Ryujiro
    Yamamoto, Masashi
    Shindo, Joe
    Hataji, Osamu
    Yoshida, Norio
    Kojima, Eiji
    Hasegawa, Yoshinori
    Saito, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR plus NSCLC
    Chen, S.
    Zhu, H.
    Jin, M.
    Liu, Z.
    Li, J.
    Hong, C.
    Li, T.
    Zhu, X.
    Meng, L.
    Qi, D.
    Zhang, X.
    Ma, T.
    Dong, L.
    Teng, L.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S681 - S682
  • [25] Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
    Zhang, Zhonghan
    Zeng, Kangmei
    Zhao, Shen
    Zhao, Yuanyuan
    Hou, Xue
    Luo, Fan
    Lu, Feiteng
    Zhang, Yaxiong
    Zhou, Ting
    Ma, Yuxiang
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [26] Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
    Nakamura, Atsushi
    Inoue, Akira
    Morita, Satoshi
    Hosomi, Yukio
    Kato, Terufumi
    Fukuhara, Tatsuro
    Gemma, Akihiko
    Takahashi, Kazuhisa
    Fujita, Yuka
    Harada, Toshiyuki
    Minato, Koichi
    Takamura, Kei
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Activating and Resistance Mutations of EGFR in Peruvian Patients with Metastatic NSCLC
    Gomez De la Torre, Juan C.
    Barletta, Claudia
    Storace, Angelo M.
    Piscocha, Christian
    Landa, Jose
    Roe, Carlos
    Roe, Eduardo
    Leiva, Manuel
    Mas, Luis
    Casavilca, Sandro
    Barrionuevo, Carlos
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S588 - S588
  • [28] Intermittent Chemotherapy and Erlotinib for Advanced NSCLC with EGFR Activating Mutations
    Zwitter, M.
    Kovac, V.
    Rajer, M.
    Stanic, K.
    Vrankar, M.
    Kern, I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S216 - S216
  • [29] Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
    Lam, T. C.
    Tsang, K. C.
    Choi, H. C.
    Lee, V. H.
    Lam, K. O.
    Chiang, C. L.
    So, T. H.
    Chan, W. W.
    Nyaw, S. F.
    Lim, F.
    Lau, J. O.
    Chik, J.
    Kong, F. M.
    Lee, A. W.
    LUNG CANCER, 2021, 159 : 18 - 26
  • [30] Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
    Sato, Miyuki
    Watanabe, Satoshi
    Tanaka, Hiroshi
    Nozaki, Koichiro
    Arita, Masashi
    Takahashi, Miho
    Shoji, Satoshi
    Ichikawa, Kosuke
    Kondo, Rie
    Aoki, Nobumasa
    Hayashi, Masachika
    Ohshima, Yasuyoshi
    Koya, Toshiyuki
    Ohashi, Riuko
    Ajioka, Yoichi
    Kikuchi, Toshiaki
    PLOS ONE, 2019, 14 (04):
12345